TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

ID#: NCT04485013

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 1

Recruitment Status: Recruiting

Start Date: July 14, 2020

End Date: June 01, 2027

Contact Information:
Tizona Therapeutics, Inc.
888-585-2990
Summary: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Eligibility: Abbreviated

Inclusion Criteria:

1. Subject with histological diagnosis of advanced/metastatic cancer [currently enrolling in CRC only]

2. Age 18 years or older, is willing and able to provide informed consent

3. Evidence of measurable disease

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 AND life expectancy of at least 12 weeks Abbreviated

Exclusion Criteria:

1. History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody

2. Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study

3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy

4. History of severe autoimmune disease

5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Find a Clinical Trial Find Cancer Clinical Trials